A natural compound found in Aloe vera may offer new hope in the search for treatments for Alzheimer's disease, according to a recent study published in Current Pharmaceutical Analysis. While Aloe vera is widely known for its use in skin care, researchers say it also contains bioactive compounds that could influence key processes involved in brain health.
Alzheimer’s disease is a progressive neurological condition that affects memory, thinking, and behavior. One of the major changes seen in people with the disease is a decline in acetylcholine, a chemical messenger that allows brain cells to communicate. As acetylcholine levels fall, memory and cognitive function worsen.
The study focused on two enzymes—acetylcholinesterase (AChE) and butyrylcholinesterase (BChE)—which are responsible for breaking down acetylcholine in the brain. Slowing the activity of these enzymes is a well-established treatment strategy in Alzheimer’s disease, as it helps preserve acetylcholine levels and reduce symptoms.
Using computer-based research methods known as in silico analysis, scientists tested several compounds derived from Aloe vera to see how effectively they interact with these enzymes. The methods included molecular docking and molecular dynamics simulations, which predict how strongly and how stably a compound binds to a target enzyme.
Among the compounds tested, beta-sitosterol showed the strongest interaction with both AChE and BChE. It demonstrated high binding affinity and stable enzyme interactions, suggesting it could act as a dual inhibitor. Researchers say this is significant because targeting both enzymes may offer better symptom control in Alzheimer’s disease.
The team also assessed the safety and drug-like properties of the compounds using ADMET analysis, which predicts how a substance behaves in the body. Beta-sitosterol showed favorable absorption and low toxicity, indicating potential suitability for further development.
While the findings are promising, researchers caution that the study was based on computer simulations. Laboratory studies and clinical trials will be needed to confirm effectiveness and safety in humans. Nonetheless, the research highlights the potential of plant-based compounds as future treatments for Alzheimer’s disease.
REFERENCE: Meriem Khedraoui, Fatima Zahra Guerguer, El Mehdi Karim, Abdelkbir Errougui, Samir Chtita. In silico exploration of Aloe vera leaf compounds as dual AChE and BChE inhibitors for Alzheimer’s disease therapy. Current Pharmaceutical Analysis, 2025; 21 (4): 238 DOI: 10.1016/j.cpan.2025.03.005
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.